此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A166在晚期实体恶性肿瘤患者中的研究

评估 A166 在不可切除、局部晚期或转移性 HER2 表达实体瘤患者中的安全性、耐受性、药代动力学和初步疗效的 I 期研究 (KL166-I-01-CTP)

This is a single arm, open-label, dose-escalation and dose-expansion phase I study evaluating A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.

研究概览

地位

完全的

条件

干预/治疗

详细说明

The first stage will determine the recommended stage 2 dose (RS2D) in patients with unresectable, locally advanced or metastatic HER2-expressing solid tumors based on safety, tolerability, pharmacokinetic characteristics and antitumor activity. The second stage will assess the safety, tolerability, pharmacokinetic characteristics and antitumor activity in dose-expansion cohorts (RS2D:3.6 mg/kg, 4.8 mg/kg and 6.0 mg/kg dose groups).

研究类型

介入性

注册 (实际的)

129

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Shanghai Municipality
      • Shanghai、Shanghai Municipality、中国、200032
        • Fudan University Shanghai Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Voluntarily sign informed consent form;
  2. Age ≥ 18 years old, no gender limit;
  3. Patients had a histologically confirmed incurable locally advanced or metastatic solid tumors;
  4. Determined HER2-positive disease (detected by ISH or NGS) or HER2-expressing disease by evaluation or detection. Definition of HER2 expression in this study: Immunohistochemistry [IHC] ≥ 1+;
  5. Patients unable to benefit from the available standard treatment according to the judgment of the investigator;
  6. White blood cell count (WBC) ≥ 4.0×109/L or ≥ lower limit of normal value; Neutrophil count (NEUT) ≥ 1.5×109/L; Platelet count (PLT) ≥ 100×109/L; Hemoglobin concentration ≥ 9.0 g/dL;
  7. Total bilirubin (TBIL) ≤ 1.5×ULN. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN). For patients with liver metastases, ALT and AST ≤ 5 times ULN, and for patients with liver and/or bone metastases, alkaline phosphatase ≤ 5 times ULN;
  8. Creatinine clearance rate ≥ 50 ml/min;
  9. Patients had an Eastern Cooperative Oncology Group (ECOG)performance status of 0 or 1, the expected survival time is ≥ 3 months;
  10. During the study period and within 7 months after the final administration of A166, patients with fertility (regardless of male and female) must receive effective medical contraceptive measures;
  11. The patients must recover from all acute toxicities of the previous treatment (relieved to grade 1 or baseline), except for hair loss and vitiligo;

Exclusion Criteria:

  1. Severe or uncontrollable heart disease requiring treatment, or grade 3 or 4 congestive heart failure according to the New York Society of Cardiology (NYHA), or unstable angina pectoris that cannot be controlled by drugs, or history of myocardial infarction within 6 months prior to enrollment, or severe arrhythmia requiring medical treatment (except for atrial fibrillation or paroxysmal supraventricular tachycardia);
  2. History of ≥ Grade 3 allergic reaction to trastuzumab;
  3. Permanent with drawal of trastuzumab due to any previous toxicity;
  4. Patients with brain metastases who have symptoms or who have received the radiotherapy or surgery within 3 months before the first administration;
  5. Patients requiring oxygen therapy in daily activities;
  6. Grade 2 or higher peripheral neuropathy;
  7. Any chemotherapy, hormone therapy (except dexamethasone), radiotherapy, immunotherapy or biological therapy received within 4 weeks before the first administration;
  8. Prior-treatment with other clinical research drugs within 4 weeks before the first administration;
  9. Patients who have undergone major surgery within 4 weeks before the first administration;
  10. Active hepatitis B (hepatitis B surface antigen positive and HBV-DNA higher than the upper limit of reference value) or hepatitis C (positive hepatitis C virus antibody and HCV-RNA higher than the upper limit of reference value); current or past alcoholics ; Liver cirrhosis;
  11. Known active human immunodeficiency virus (HIV);
  12. Systemic diseases that cannot be controlled, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, interstitial lung disease, glaucoma, etc according to investigator's judgment;
  13. Current pregnancy or lactation;
  14. QTc interval> 470 ms according to the baseline measurement:;
  15. Left ventricular ejection fraction (LVEF) <45% according to the echocardiogram (ECHO) or multi-gate circuit controlled acquisition (MUGA) ;
  16. Previous cumulative doxorubicin accumulation > 360 mg/m2 or its equivalent dose;

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:The first stage(Dose-escalation)

According to the initial dose, the highest dose and the modified Fibonacci method, the dose escalation of A166 for injection is designed as: 0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg, 1.2 mg/kg, 2.4 mg/kg, 3.6 mg/kg, 4.8 mg/kg (the highest dose is tentatively set at 4.8 mg/kg).

A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

实验性的:The second stage(Dose-expansion)

The administered dose of A166 for injection is RS2D obtained in the first stage .

A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:up to 24 month

The percentage of patients with CR and PR assessed by investigators according to RECIST v 1.1

up to 24 month

次要结果测量

结果测量
措施说明
大体时间
Duration of Response (DOR)
大体时间:up to 24 month

From the date that response criteria are first met to the first occurrence of PD as determined by the investigators according to RECIST v1.1 or death from any cause, whichever occurs first

up to 24 month
Progression-free survival(PFS)
大体时间:up to 24 month

PFS, defined as the active comparator arm frist dosing of A166 injection to the first occurrence of disease progression as determined by the investigators according to RECIST v1.1 or death from any cause, whichever occurs first

up to 24 month
Overall Survival (OS)
大体时间:up to 24 month

OS, defined as the time from randomization to death or lose of follow, whichever occurs first

up to 24 month

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2018年8月1日

初级完成 (实际的)

2026年4月9日

研究完成 (实际的)

2026年4月9日

研究注册日期

首次提交

2022年3月7日

首先提交符合 QC 标准的

2022年4月4日

首次发布 (实际的)

2022年4月5日

研究记录更新

最后更新发布 (实际的)

2026年10月1日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • KL166-I-01-CTP

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅